Table 3.
Waning of serum concentrations of antibodies to specific pneumococcal serotypes following PCV-13 vaccination
| Serotype | Median (IQR) Serum Antibody Concentration (μg/mL) |
Median (IQR) Percent Decline |
|
|---|---|---|---|
| Early Post-Vaccine (Age 5 Months) |
Late Post-Vaccine (Age 12 Months) |
||
| 1 | 1.66 (0.51–4.97) | 0.34 (0.06–0.66) | 83% (67%–90%) |
| 3 | 1.04 (0.60–1.71) | 0.24 (0.17–0.37) | 75% (58%–86%) |
| 4 | 4.34 (2.20–8.57) | 0.37 (0.18–0.80) | 91% (82%–96%) |
| 5 | 1.96 (1.14–3.29) | 0.37 (0.21–0.63) | 83% (69%–90%) |
| 6A | 2.29 (0.97–4.37) | 0.86 (0.58–1.61) | 55% (8%–75%) |
| 6B | 3.82 (1.51–10.10) | 0.43 (0.21–1.10) | 86% (62%–93%) |
| 7F | 3.32 (1.91–5.26) | 0.58 (0.38–0.96) | 81% (68%–89%) |
| 9V | 3.38 (1.42–5.75) | 0.30 (0.15–0.56) | 90% (82%–94%) |
| 14 | 8.10 (2.40–13.35) | 2.42 (1.19–5.12) | 59% (18%–81%) |
| 18C | 2.99 (1.29–4.71) | 0.17 (0.06–0.33) | 93% (86%–97%) |
| 19A | 4.71 (2.41–6.88) | 1.39 (0.76–4.78) | 62% (0%–85%) |
| 19F | 6.24 (2.96–11.55) | 1.08 (0.52–2.47) | 84% (61%–93%) |
| 23F | 2.32 (1.21–4.21) | 0.34 (0.14–0.70) | 85% (61%–94%) |
IQR, interquartile range; μg, microgram; mL, milliliter